phase i dose escalation of imc-f106c - first prame × cd3 immtac bispecific protein in solid tumors
Published 2 years ago • 162 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
8:23
results from a phase i study of amg 160
-
12:17
updated iv and sc results from a phase i dose escalation study of forimtamig with rrmm patients
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
0:30
bio sb - 2020 new prame antibody for ihc
-
1:47
an overview of the ma17r trial in breast cancer
-
4:55
3 future prostate cancer treatment advancements | mark scholz, md & mark moyad, md | 2021 pcri
-
30:49
the pi3k / akt / mtor pathway and cancer part 2
-
7:02
immunohistochemistry (ihc)
-
1:46
esmo oncologypro - intro by dr. e. smyth
-
2:10
overview of a phase ii clinical trial of isatuximab
-
2:12
monitoring disease in high-risk mm: euroflow with mass spectrometry
-
2:39
tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma
-
1:38
dr. sosman on the mechanism of action of ipilimumab in melanoma
-
1:16
preliminary results of ibruntinib in combination with fcr chemotherapy for cll
-
2:27
proteinseq protein quantitation system – the revolution in immunoassays is here
-
3:33
results of the phase ii randomized forte trial
-
1:27
probing the role of carbamylation in cell signaling and disease processes
-
1:53
esmo oncologypro - presentation by dr. e. smyth
-
2:01
ce-icp-ms for quantification-iron redox species (fe(ii), fe(iii)) l protocol preview
-
2:01
treating imcd: from precision medicine to clinical trial
-
7:09
how to run the invitrogen proquantum high sensitivity immunoassay kit
-
5:22
chemoimmunotherapy for es sclc: impower133 trial